190 related articles for article (PubMed ID: 31596080)
21. Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site.
Wang J; Yang D; Cheng X; Yang L; Wang Z; Dai A; Cai X; Zhang C; Yuliantie E; Liu Q; Jiang H; Liu H; Wang MW; Yang H
ACS Chem Biol; 2021 Nov; 16(11):2444-2452. PubMed ID: 34570476
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
Tinsley IC; Borner T; Swanson ML; Chepurny OG; Doebley SA; Kamat V; Sweet IR; Holz GG; Hayes MR; De Jonghe BC; Doyle RP
J Med Chem; 2021 Mar; 64(6):3479-3492. PubMed ID: 33677970
[TBL] [Abstract][Full Text] [Related]
23. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
[TBL] [Abstract][Full Text] [Related]
24. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
25. An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke.
Zhang H; Liu Y; Guan S; Qu D; Wang L; Wang X; Li X; Zhou S; Zhou Y; Wang N; Meng J; Ma X
PLoS One; 2016; 11(2):e0148827. PubMed ID: 26863436
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Drucker DJ
Cell Metab; 2018 Apr; 27(4):740-756. PubMed ID: 29617641
[TBL] [Abstract][Full Text] [Related]
27. Structural insights into probe-dependent positive allosterism of the GLP-1 receptor.
Bueno AB; Sun B; Willard FS; Feng D; Ho JD; Wainscott DB; Showalter AD; Vieth M; Chen Q; Stutsman C; Chau B; Ficorilli J; Agejas FJ; Cumming GR; Jiménez A; Rojo I; Kobilka TS; Kobilka BK; Sloop KW
Nat Chem Biol; 2020 Oct; 16(10):1105-1110. PubMed ID: 32690941
[TBL] [Abstract][Full Text] [Related]
28. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently.
Cheong YH; Kim MK; Son MH; Kaang BK
Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947
[TBL] [Abstract][Full Text] [Related]
29. Discovery of small molecule positive allosteric modulators of the secretin receptor.
Dengler DG; Harikumar KG; Pollari S; Sun Q; Brown BT; Shinoki-Iwaya A; Ardecky R; Miller LJ; Sergienko EA
Biochem Pharmacol; 2021 Mar; 185():114451. PubMed ID: 33545115
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro biological evaluation of new pyrimidines as glucagon-like peptide-1 receptor agonists.
AlNeyadi SS; Adem A; Amer N; Salem AA; Abdou IM
Bioorg Med Chem Lett; 2017 Nov; 27(22):5071-5075. PubMed ID: 28988756
[TBL] [Abstract][Full Text] [Related]
31. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
[TBL] [Abstract][Full Text] [Related]
32. The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists.
Fang H; Niu B; Chen Q
Curr Med Chem; 2024; 31(20):2921-2943. PubMed ID: 37062063
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure- based drug design.
O'Brien A; Andrews SP; Baig AH; Bortolato A; Brown AJH; Brown GA; Brown SH; Christopher JA; Congreve M; Cooke RM; De Graaf C; Errey JC; Fieldhouse C; Jazayeri A; Marshall FH; Mason JS; Mobarec JC; Okrasa K; Steele KN; Southall SM; Teobald I; Watson SP; Weir M
Bioorg Med Chem Lett; 2019 Oct; 29(20):126611. PubMed ID: 31447084
[TBL] [Abstract][Full Text] [Related]
34. Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists.
Girdhar K; Dehury B; Kumar Singh M; Daniel VP; Choubey A; Dogra S; Kumar S; Mondal P
J Biomol Struct Dyn; 2019 Sep; 37(15):3976-3986. PubMed ID: 30296922
[TBL] [Abstract][Full Text] [Related]
35. Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.
Li Y; Zheng X; Yi X; Liu C; Kong D; Zhang J; Gong M
FASEB J; 2017 Jun; 31(6):2603-2611. PubMed ID: 28270518
[TBL] [Abstract][Full Text] [Related]
36. Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor.
Cong Z; Chen LN; Ma H; Zhou Q; Zou X; Ye C; Dai A; Liu Q; Huang W; Sun X; Wang X; Xu P; Zhao L; Xia T; Zhong W; Yang D; Eric Xu H; Zhang Y; Wang MW
Nat Commun; 2021 Jun; 12(1):3763. PubMed ID: 34145245
[TBL] [Abstract][Full Text] [Related]
37. Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects.
Zhang H; Sturchler E; Zhu J; Nieto A; Cistrone PA; Xie J; He L; Yea K; Jones T; Turn R; Di Stefano PS; Griffin PR; Dawson PE; McDonald PH; Lerner RA
Nat Commun; 2015 Dec; 6():8918. PubMed ID: 26621478
[TBL] [Abstract][Full Text] [Related]
38. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?
Doggrell SA
Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389
[TBL] [Abstract][Full Text] [Related]
39. Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects.
Zhao L; Wang B; Wang L; Zhao X; Chen Z; Sun L
Org Biomol Chem; 2019 Sep; 17(33):7760-7771. PubMed ID: 31389463
[TBL] [Abstract][Full Text] [Related]
40. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
